A Phase 2 Efficacy and Safety, Open-label, Multicenter Study of Imprime PGG Injection in Combination with Cetuximab in Patients with Stage IV KRAS-Mutant Colorectal Cancer

BACKGROUND: Imprime PGG is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert anti-tumor activity against complement opsonized tumor cells. In patients with KRAS-mutant colorectal cancer (CRC), cetuximab alone is ineffective; however, it can bind to tumor cell...

Full description

Saved in:
Bibliographic Details
Published in:Clin Colorectal Cancer
Main Authors: Segal, Neil H., Gada, Purvi, Senzer, Neil, Gargano, Michele A., Patchen, Myra L., Saltz, Leonard B.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5621519/
https://ncbi.nlm.nih.gov/pubmed/26975418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2016.02.013
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items